Cydy early on will have no problem distributing Leronlimab for EAMS in the UK and potentially , if it’s approved this year and the first drug approved after Remdisivir . But once Lilly and Regeneron, possibly others jump in it will take a sales team to help doctors differentiate between the options . And in other applications he will also need to do the same . It would be in Cytodyns best interests to do so from a growth standpoint . I ha e learned in my career sometimes the best product doesn’t win; it’s the best sales and Marketing that does .